Original article

European Journal of Nuclear Medicine

, Volume 22, Issue 4, pp 339-345

First online:

Iodine-123N- methyl-4-iododexetimide: a new radioligand for single-photon emission tomographic imaging of myocardial muscarinic receptors

  • Rodney J. HicksAffiliated withHeidelberg Hospital
  • , Michael KassiouAffiliated withBiomedicine and Health Division, Australian Nuclear Science and Technology Organisation
  • , Peter EuAffiliated withHeidelberg Hospital
  • , Andrew G. KatsifisAffiliated withBiomedicine and Health Division, Australian Nuclear Science and Technology Organisation
  • , Maria GarraAffiliated withHeidelberg Hospital
  • , John PowerAffiliated withHeidelberg Hospital
  • , Ljubco NajdovskiAffiliated withBiomedicine and Health Division, Australian Nuclear Science and Technology Organisation
  • , Richard M. LambrechtAffiliated withBiomedicine and Health Division, Australian Nuclear Science and Technology Organisation

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Cardiac muscarinic receptor ligands suitable for positron emission tomography have previously been characterised. Attempts to develop radioligands of these receptors suitable for single-photon emission tomographic (SPET) imaging have not been successful due to high lung retention and high non-specific binding of previously investigated potential tracers. The purpose of this study was to evaluate the biodistribution and in vivo imaging characteristics of a new radiopharmaceutical, [123I]N-methyl-4-iododexetimide. Biodistribution studies performed in rats showed high cardiac uptake (2.4% ID/g) 10 min after injection with a heart to lung activity ratio of 5:1. Specificity and stereo selectivity of cardiac binding were demonstrated using blocking experiments in rats. Dynamic imaging studies in anaesthetised greyhounds demonstrated rapid and high myocardial uptake and low lung binding with stable heart to lung activity ratios of >2.5:1 between 10 and 30 min, making SPET imaging feasible. Administration of an excess of an unlabelled muscarinic antagonist, methyl-quinuclidinyl benzylate rapidly displaced myocardial activity to background levels and the pharmacologically inactive enantiomer, [123I]N-methyl-4-iodolevetimide, had no detectable cardiac uptake, indicating specific and stereoselective muscarinic receptor binding. SPET revealed higher activity in the inferior than in the anterior wall, this being consistent with previously described regional variation of cardiac parasympathetic innervation. [123I]N-methyl-4-iododexetimide shows promise as an imaging agent for muscarinic receptor distribution in the heart and may be helpful in evaluating diverse cardiac diseases associated with altered muscarinic receptor function, including heart failure and diabetic heart disease.

Key words

Muscarinic receptor Parasympathetic nervous system Single-photon emission tomography Cardiac uptake